Grasustek (Pegfilgrastim)

Grasustek is indicated for use in adult patients receiving myelosuppressive chemotherapy to reduce the incidence of febrile neutropenia.

• Prophylaxis of chemotherapy‑induced neutropenia in patients with solid tumors.
• Support for patients with hematologic malignancies undergoing high‑dose chemotherapy.
• Use when the anticipated risk of neutropenia is ≥20% based on chemotherapy regimen.
• Administration as a single dose per chemotherapy cycle, typically 24 hours after chemotherapy completion.
• May be considered in patients with prior episodes of neutropenia despite standard G‑CSF therapy.

The safety profile of pegfilgrastim reflects its pharmacologic activity on bone marrow; reported adverse events are categorized as common or serious.

Common

• Bone pain, often in the back, hips, or sternum.
• Mild injection‑site reactions such as erythema or swelling.
• Fatigue or generalized weakness.
• Nausea or mild gastrointestinal discomfort.

Serious

• Splenic rupture or enlargement.
• Acute respiratory distress syndrome (ARDS).
• Severe allergic reactions, including anaphylaxis.
• Capillary leak syndrome.

When prescribing Grasustek, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

• Avoid use in patients with known hypersensitivity to pegfilgrastim or its excipients.
• Use caution in individuals with a history of splenic disorders or abdominal trauma.
• Assess renal or hepatic impairment, as clearance may be altered.
• Monitor complete blood counts before and after administration to detect unexpected leukocytosis.
• Consider dose adjustment or alternative therapy in pregnant or breastfeeding women only if benefits outweigh risks.
• Be aware of potential for bone pain; provide appropriate analgesia if needed.

Pegfilgrastim may interact with other medications or biologics; understanding these interactions helps to minimize clinical complications.

Avoid

• Concurrent use with other colony‑stimulating factors (e.g., filgrastim) due to overlapping mechanisms.
• Live vaccines administered within 4 weeks of pegfilgrastim, as immune response may be altered.

Use with caution

• Chemotherapeutic agents that cause profound myelosuppression; timing of pegfilgrastim should follow chemotherapy completion.
• Corticosteroids may mask bone‑pain symptoms.
• Anticoagulants, as severe thrombocytopenia could increase bleeding risk if it occurs.
• Immunosuppressive biologics, where combined effects on immune modulation require close monitoring.